An Exploratory Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP) in Israel
Thousands of patients are diagnosed each year with metastatic cancer; however, about 3-5% of
them are diagnosed with Cancer of Unknown Primary (CUP). In order to identify the optimal
treatment plan for individual patients with CUP, the primary tumor site must be identified.
Patients undergo a wide range of costly, time-consuming, and inefficient tests to identify
the primary site of origin, often to no avail.
In this era of targeted therapies, the accurate diagnosis of the primary tumor can be
crucial. miRview™ mets is a new molecular diagnostic tool that identifies the
tissue-of-origin of metastatic tumors, with 90% sensitivity.
Observational Model: Case Control, Time Perspective: Prospective
To compare the cost-effectiveness of miRview™ mets test with conventional work-up in cancer of unknown primary (CUP) patients, by comparing total cost and time of the diagnostic process (including hospitalization time) from day 1 of the study to the decision on treatment program
Salomon Shtemmer, MD
Clalit Health Services
Israel: Ministry of Health